viral oncogene proteins

Summary

Summary: Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities.

Top Publications

  1. ncbi Papillomaviruses and cancer: from basic studies to clinical application
    Harald zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Nat Rev Cancer 2:342-50. 2002
  2. ncbi Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
    J M Walboomers
    Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Pathol 189:12-9. 1999
  3. ncbi The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
    M Scheffner
    Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892
    Cell 75:495-505. 1993
  4. pmc Efficient intracellular assembly of papillomaviral vectors
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4263, USA
    J Virol 78:751-7. 2004
  5. ncbi The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
    N Dyson
    Cold Spring Harbor Laboratory, NY 11724
    Science 243:934-7. 1989
  6. ncbi Human papillomavirus immortalization and transformation functions
    Karl Munger
    Department of Pathology, Harvard Medical School, Armenise Building 544, 200 Longwood Avenue, Boston, MA 02115 5701, USA
    Virus Res 89:213-28. 2002
  7. pmc Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase
    S Nakagawa
    Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey 08855, USA
    Mol Cell Biol 20:8244-53. 2000
  8. pmc Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein
    T Kiyono
    Laboratory of Viral Oncology, Aichi Cancer Center, Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464, Japan
    Proc Natl Acad Sci U S A 94:11612-6. 1997
  9. pmc Arrangement of L2 within the papillomavirus capsid
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
    J Virol 82:5190-7. 2008
  10. pmc Pathogenesis of human papillomaviruses in differentiating epithelia
    Michelle S Longworth
    Department of Microbiology Immunology, The Fineberg Medical School, Northwestern University, 303 E Chicago Ave, Chicago, IL 60611, USA
    Microbiol Mol Biol Rev 68:362-72. 2004

Research Grants

  1. Genomic instability induced by the HPV-16 E7 oncoprotein
    Stefan Duensing; Fiscal Year: 2009
  2. Dendritic Cell Immunotherapy for Cervical Cancer
    Alessandro Santin; Fiscal Year: 2004
  3. A Phase I/II Trial of a Therapeutic HPV Vaccine
    Cornelia Trimble; Fiscal Year: 2004
  4. THERAPEUTIC VACCINES FOR HPV DISEASES
    Cornelia Trimble; Fiscal Year: 2005
  5. Transcripitonal and Genetic Profiles in HNSCCs
    Elaine Smith; Fiscal Year: 2008
  6. CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16
    Mayumi Nakagawa; Fiscal Year: 2002
  7. Therapeutic DNA-MVA prime boost vaccination for HPV disease
    Cornelia Trimble; Fiscal Year: 2007
  8. International Collaborative HNC Research
    Elaine Smith; Fiscal Year: 2007
  9. GENETIC EPIDEMIOLOGY AND MECHANISMS IN ORAL CANCER
    Elaine Smith; Fiscal Year: 2003
  10. Papillomavirus E2 as a cervical/anal cancer drug target
    Janet Brandsma; Fiscal Year: 2005

Detail Information

Publications265 found, 100 shown here

  1. ncbi Papillomaviruses and cancer: from basic studies to clinical application
    Harald zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Nat Rev Cancer 2:342-50. 2002
    ..Epidemiological studies have underlined that HPVs are the main aetiological factor for cervical cancer. But how has this knowledge been translated into the clinic to allow the prevention, screening and treatment of cervical cancer?..
  2. ncbi Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
    J M Walboomers
    Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Pathol 189:12-9. 1999
    ..The extreme rarity of HPV-negative cancers reinforces the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening...
  3. ncbi The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
    M Scheffner
    Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892
    Cell 75:495-505. 1993
    ..The ubiquitination of p53 requires the E1 enzyme and a novel E2 in mammalian cells, while E3 activity is conferred by the E6-E6-AP complex. Furthermore, E6-AP appears to have ubiquitin-protein ligase activity in the absence of E6...
  4. pmc Efficient intracellular assembly of papillomaviral vectors
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4263, USA
    J Virol 78:751-7. 2004
    ..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism...
  5. ncbi The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
    N Dyson
    Cold Spring Harbor Laboratory, NY 11724
    Science 243:934-7. 1989
    ..These results suggest that these three DNA viruses may utilize similar mechanisms in transformation and implicate RB binding as a possible step in human papilloma virus-associated carcinogenesis...
  6. ncbi Human papillomavirus immortalization and transformation functions
    Karl Munger
    Department of Pathology, Harvard Medical School, Armenise Building 544, 200 Longwood Avenue, Boston, MA 02115 5701, USA
    Virus Res 89:213-28. 2002
    ..This paper will review the state of the field at the time of the 19th International Papillomavirus Workshop in September 2001 with respect to the HPV encoded oncoproteins...
  7. pmc Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase
    S Nakagawa
    Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey 08855, USA
    Mol Cell Biol 20:8244-53. 2000
    ....
  8. pmc Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein
    T Kiyono
    Laboratory of Viral Oncology, Aichi Cancer Center, Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464, Japan
    Proc Natl Acad Sci U S A 94:11612-6. 1997
    ..These results suggest an intriguing possibility that interaction between the E6 protein and hDLG or other PDZ domain-containing proteins could be an underlying mechanism in the development of HPV-associated cancers...
  9. pmc Arrangement of L2 within the papillomavirus capsid
    Christopher B Buck
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
    J Virol 82:5190-7. 2008
    ..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle...
  10. pmc Pathogenesis of human papillomaviruses in differentiating epithelia
    Michelle S Longworth
    Department of Microbiology Immunology, The Fineberg Medical School, Northwestern University, 303 E Chicago Ave, Chicago, IL 60611, USA
    Microbiol Mol Biol Rev 68:362-72. 2004
    ..The characterization of the cellular targets of these viral proteins and the mechanisms regulating the differentiation-dependent viral life cycle remain active areas for the study of these important human pathogens...
  11. ncbi siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells
    Karin Butz
    Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, Heidelberg D 69120, Germany
    Oncogene 22:5938-45. 2003
    ..Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells...
  12. ncbi Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference
    Ming Jiang
    YCR P53 Research Group, Department of Biology, University of York, York YO10 5DD, UK
    Oncogene 21:6041-8. 2002
    ....
  13. pmc Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, School of Medicine, Health Sciences Center, University of New Mexico, Albuquerque, NM 87111, USA
    J Clin Microbiol 44:1755-62. 2006
    ..HPV-16 E2 expressed from intact episomes may act in trans to regulate integrated genome expression of E6 and E7...
  14. pmc The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities
    Anny Shai
    McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA
    Cancer Res 67:1626-35. 2007
    ..E6 also prevented the expression of p16 in tumors of the reproductive tract through a mechanism mediated by the interaction of E6 with alpha-helix partners...
  15. ncbi Biological activities and molecular targets of the human papillomavirus E7 oncoprotein
    K Munger
    Department of Pathology and Harvard Center for Cancer Biology, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 20:7888-98. 2001
    ..The transforming activities of E7 largely reflect this important function...
  16. pmc Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein
    S S Lee
    Division of Molecular Virology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 94:6670-5. 1997
    ....
  17. ncbi Association of human papillomavirus types 16 and 18 E6 proteins with p53
    B A Werness
    Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, MD 20892
    Science 248:76-9. 1990
    ....
  18. pmc Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites
    S T Oh
    Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, Illinois 60611, USA
    J Virol 75:5559-66. 2001
    ..This indicates that it is the combinatorial binding of factors to Myc and Sp1 cis elements that is responsible for hTERT induction by E6...
  19. pmc The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors
    Medha S Darshan
    Biology Department, Boston College, Higgins Hall Room 578, 140 Commonwealth Avenue, Chestnut Hill, MA 02467, USA
    J Virol 78:12179-88. 2004
    ..Together the data suggest that HPV16 L2 interacts via its NLSs with a network of karyopherins and can enter the nucleus via several import pathways mediated by Kapalpha(2)beta(1) heterodimers, Kapbeta(2), and Kapbeta(3)...
  20. pmc Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle
    Tomomi Nakahara
    McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, 53706, USA
    J Virol 79:13150-65. 2005
    ..These data support the hypothesis that E1(circumflex)E4 is a multifunctional protein and that the different properties of E1(circumflex)E4 contribute to different processes in both the early and late stages of the virus life cycle...
  21. ncbi Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16
    G Veress
    Department of Microbiology, University Medical School of Debrecen, Hungary
    J Gen Virol 80:1035-43. 1999
    ..The transcriptional transactivation potentials of the HPV-16 E2 isolates differed only slightly from each other, and the differences seemed to be independent of the taxonomic position of the isolates...
  22. pmc Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1
    Thomas Iftner
    Sektion Experimentelle Virologie, Universitatsklinikum Tuebingen, Elfriede Aulhorn Strasse 6, D 72076 Tuebingen, Germany
    EMBO J 21:4741-8. 2002
    ..These data identify a novel link between small DNA tumour viruses and DNA repair pathways, and suggest a novel explanation for the development of genomic instability in tissue cells persistently infected with papillomaviruses...
  23. pmc Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Invest 112:109-17. 2003
    ..Thus, coadministration of DNA vaccines with DNA encoding antiapoptotic proteins represents an innovative approach to enhance DNA vaccine potency...
  24. pmc Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7
    N R Chu
    StressGen Biotechnologies Corporation, Victoria, B C, Canada, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Clin Exp Immunol 121:216-25. 2000
    ..These studies extend previous observations on the induction of cytotoxic T lymphocytes by hsp fusion proteins and are consistent with the clinical application of hspE7 as an immunotherapy for human cervical and anal dysplasia and cancer...
  25. pmc Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes
    M Nees
    Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Bethesda, Maryland, USA
    J Virol 75:4283-96. 2001
    ..Thus, high-level expression of the HPV-16 E6 protein in differentiating keratinocytes directly alters expression of genes that influence host resistance to infection and immune function...
  26. pmc Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology
    S M A Kulmala
    Department of Oral Pathology, Institute of Dentistry, University of Turku, Finland
    J Clin Pathol 59:513-7. 2006
    ....
  27. ncbi Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis
    Yves Nominé
    Equipe Oncoprotéine, UMR CNRS 7100, Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sebastien Brant, BP 10413, 67412 Illkirch Cedex, France
    Mol Cell 21:665-78. 2006
    ..E6 structure-function analysis provides new clues for understanding and counteracting the complex pathways of HPV-mediated pathogenesis...
  28. pmc The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo
    Marie L Nguyen
    McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA
    J Virol 77:6957-64. 2003
    ..However, the K14E6(Delta 146-151) mice fail to display epithelial hyperplasia. These results indicate that an interaction of E6 with PDZ partners is necessary for its induction of epithelial hyperplasia...
  29. pmc Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins
    S S Lee
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Virol 74:9680-93. 2000
    ....
  30. ncbi Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo
    X Y Niu
    Department of Obstetrics and Gynecology, Sichuan University Huaxi the Second Hospital, Chengdu, Sichuan Province, China
    Int J Gynecol Cancer 16:743-51. 2006
    ..RNA interference exists, and the interference to HPV 16 E6 is specific and highly efficient both in vitro and in vivo...
  31. ncbi alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP
    C S Yoon
    Genome Research Center, Korea Research Institute of Bioscience and Biotechnology, Taejeon, 305-600, Korea
    Biochem Biophys Res Commun 283:668-73. 2001
    ..The degree of binding of HPV-VLP matched the alpha(6) integrin expression level in cell lines but was not correlated with beta(1) and beta(4) levels, which suggests that alpha(6) integrin is the main receptor of HPV type 16...
  32. ncbi Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers
    Bassam Abdulkarim
    Laboratoire UPRES EA N degrees 27 10 Radiosensibilité Radiocarcinogénèse humaine and Unité METSI, Institut Gustave Roussy, 94805 Villejuif, France
    Oncogene 21:2334-46. 2002
    ..This study provides the basis for a new anticancer strategy to enhance the antitumor effect of ionizing radiation in HPV-related cancers, without increase deleterious effects...
  33. pmc Predicting indirect readout effects in protein-DNA interactions
    Yongli Zhang
    Departments of Chemistry and Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA
    Proc Natl Acad Sci U S A 101:8337-41. 2004
    ..The sole exception was traced to differential magnesium ion binding...
  34. ncbi Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins
    Mako Narisawa-Saito
    Virology Division, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Sci 98:1505-11. 2007
    ..In the present article, the mechanisms of HPV16 E6- and E7-induced multistep carcinogenesis and recently identified functions of these onco-proteins are reviewed...
  35. ncbi Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
    Sander Zwaveling
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    J Immunol 169:350-8. 2002
    ..Because the vaccine types used in this study are easy to prepare under good manufacturing practice conditions and are safe to administer to humans, these data provide important information for future clinical trials...
  36. ncbi The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability
    Stefan Duensing
    Department of Pathology and Harvard Center for Cancer Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 62:7075-82. 2002
    ..Our results therefore suggest that HPV oncoproteins are a source for both numerical and structural chromosome instability during HPV-associated carcinogenesis...
  37. ncbi Papillomavirus E6 and E7 proteins and their cellular targets
    Trisha M Wise-Draper
    Division of Hematology Oncology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Front Biosci 13:1003-17. 2008
    ..We will summarize here current insights into E6 and E7 interactions with specific cellular targets that stimulate aspects of the viral life cycle, interfere with cell cycle controls and promote carcinogenic processes...
  38. ncbi TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16
    Uzma A Hasan
    International Agency for Research on Cancer World Health Organization, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Immunol 178:3186-97. 2007
    ....
  39. ncbi In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA
    Mitsuo Yoshinouchi
    Department of Obstetrics and Gynecology, Okayama University Medical School, 700 8558, Okayama, Japan
    Mol Ther 8:762-8. 2003
    ..Our results show HPV E6 siRNA as a candidate for gene-specific therapy for HPV-related cervical cancer...
  40. ncbi Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Cancer Res 63:6032-41. 2003
    ..Local immune infiltration may be a critical factor in potential responsiveness to vaccine therapy in HPV-associated neoplasia and should be carefully monitored in future placebo-controlled trials of immunotherapy for VIN...
  41. ncbi Mechanisms of cell transformation by papillomavirus E5 proteins
    D DiMaio
    Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Oncogene 20:7866-73. 2001
    ..Further analysis of these unique mechanisms of viral transformation will yield new insight into the regulation of growth factor receptor activity and cellular signal transduction pathways...
  42. ncbi Epidemiological and functional implications of molecular variants of human papillomavirus
    L Sichero
    Instituto Ludwig de Pesquisa sobre o Câncer, Sao Paulo, SP, Brasil
    Braz J Med Biol Res 39:707-17. 2006
    ..These results are also important for the development of vaccines and to determine the extent to which immunization with L1 virus-like particles of one variant could induce antibodies that cross-neutralize other variants...
  43. ncbi Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis
    H zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    J Natl Cancer Inst 92:690-8. 2000
    ..Modifications in host-cell genes, most likely engaged in the control of HPV gene expression in proliferating cells, emerge as important events in HPV-mediated carcinogenesis...
  44. pmc A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11
    Katharina Slupetzky
    Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Vaccine 25:2001-10. 2007
    ..Induction of cross-neutralization Ab by L2 epitopes displayed on chimeric VLP represents a possible strategy for the generation of broad-spectrum vaccines to protect against relevant mucosal HPV and associated neoplasia...
  45. ncbi Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
    Diane M Harper
    Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA
    Lancet 364:1757-65. 2004
    ....
  46. pmc Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation
    Wenyi Gu
    Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland, Research Extension, Building 1, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland 4102, Australia
    Nucleic Acids Res 35:4820-32. 2007
    ..It appears that aa-tRNAs in less-differentiated and differentiated KCs differentially match the PV Nat and Mod L1 mRNAs to regulate their translations in vitro...
  47. ncbi Transcription-modulatory activity of full-length E6 and E6*I proteins of human papillomavirus type 16
    H Shirasawa
    Department of Microbiology, School of Medicine, Chiba University, Japan
    Virology 203:36-42. 1994
    ..The transcription-modulatory functions of full-length E6 and E6*I proteins suggested that transcriptional regulation of HPVs associated with mucosal malignant lesions is complex...
  48. pmc AMF-1/Gps2 binds p300 and enhances its interaction with papillomavirus E2 proteins
    Y C Peng
    Department of Dermatology, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    J Virol 74:5872-9. 2000
    ..These results suggest that AMF-1 facilitates the recruitment of p300 and its histone acetylase activity into complexes with E2 and represents a novel mechanism of transcriptional activation...
  49. ncbi Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential
    Sara J S Simonson
    McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin 53706, USA
    Cancer Res 65:8266-73. 2005
    ....
  50. ncbi E7-transduced human breast epithelial cells show partial differentiation in three-dimensional culture
    K M Spancake
    Huntsman Cancer Institute, University of Utah, Salt Lake City 84112, USA
    Cancer Res 59:6042-5. 1999
    ..These data suggest that loss of RB in vivo would compromise differentiation, predisposing these cells to future tumor-promoting actions...
  51. ncbi Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies
    Brooke Bishop
    Department of Molecular and Computational Biology, University of Southern California, Los Angeles, California 90089, USA
    J Biol Chem 282:31803-11. 2007
    ..On the basis of these distinct surface loop structures, we have provided a molecular explanation for the type specificity of NmAbs against HPV infection...
  52. pmc A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression
    Margaret Rush
    Department of Medical Biochemistry and Microbiology, Uppsala University, Biomedical Centre, Husargatan 3, Box 582, 75123 Uppsala, Sweden
    J Virol 79:12002-15. 2005
    ....
  53. pmc Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein
    G Steger
    Institut fur Virologie der Universitat zu Koln, Cologne, Germany
    J Virol 71:50-8. 1997
    ..Our results suggest a dose-dependent regulation of the HPV18 E6/E7 promoter by E2 due to variable occupancy of its binding sites, which have antagonizing effects on the activity of the E6/E7 promoter...
  54. ncbi Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer
    Takuma Fujii
    Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 160 8582, Japan
    Int J Oncol 29:541-8. 2006
    ..These results indicate that atelocollagen-mediated delivery of siRNA HPV18 E6 and E7 can be used as a novel therapeutic approach for cervical cancer...
  55. pmc The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms
    Kirsten Kabsch
    Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany
    J Virol 76:12162-72. 2002
    ..We propose that inhibition of ligand-mediated apoptosis in human keratinocytes is a primary function of the HPV-16 E5 protein needed to prevent apoptosis at early stages of viral infection...
  56. ncbi RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin
    Lisa N Putral
    Cancer Biology Program, CICR, R Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia
    Mol Pharmacol 68:1311-9. 2005
    ..Our results provide strong evidence that loss of E6 and E7 results in increased sensitivity to cisplatin, probably because of increased p53 levels...
  57. pmc Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus
    Martin Sapp
    Department of Microbiology and Immunology, Feist Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA 71130 3932, USA
    FEBS J 276:7206-16. 2009
    ..This minireview summarizes recent advances in our understanding of cell surface events, internalization and the subsequent intracellular trafficking of papillomaviruses...
  58. pmc Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31
    Choongho Lee
    Department of Microbiology Immunology, Feinberg School of Medicine, Northwestern University, Mail Code S213, 320 E Superior Street, Chicago, IL 60611 3010, USA
    J Virol 78:12366-77. 2004
    ..These results suggest that binding of E6 to PDZ proteins modulates the early viral functions such as proliferation and maintenance of the viral copy number in undifferentiated cells...
  59. pmc Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination
    Tae Heung Kang
    Laboratory of Infection and Immunology, Graduate School of Medicine, Korea University, Gyeonggi Do, South Korea
    Cancer Res 67:802-11. 2007
    ..These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments...
  60. ncbi Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18
    Deborah Stewart
    Institute of Parasitology, Macdonald Campus, McGill University, Montreal, Canada, H9X 3V9
    J Gen Virol 85:1419-26. 2004
    ..These results provide insight into the cellular modulation of E6 protein levels from both high-risk and low-risk HPV types...
  61. pmc Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein
    Yi Zhang
    Molecular and Computational Biology, University of Southern California, 1050 Childs Way, MCB201, Los Angeles, CA 90089, USA
    J Virol 81:3618-26. 2007
    ..In addition to its novel insights into the biochemistry of PDZ interactions, this study is important for understanding HPV-induced oncogenesis; this could provide a basis for developing antiviral and anticancer compounds...
  62. ncbi Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells
    J Wang
    Center for Molecular Biology of Oral Diseases, College of Dentistry (M/C 860, University of Illinois at Chicago, 60612, USA
    Oncogene 20:4740-9. 2001
    ..Taken together, this study suggests that targeted inhibition of Rb proteolysis will be required for restoring Rb function in HPV-containing cervical cancer cells...
  63. pmc Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene
    Xiaomin Zhao
    Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Husargatan 3, Box 582, 751 23 Uppsala, Sweden
    J Virol 78:10888-905. 2004
    ....
  64. ncbi E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I
    G Hossein Ashrafi
    Institute of Comparative Medicine, Department of Pathological Sciences, Glasgow University, Glasgow G61 1QH, Scotland, UK
    Int J Cancer 113:276-83. 2005
    ..Selective downregulation of cell surface HLA class I molecules may allow the virus to establish infection by avoiding immune clearance of virus-infected cells by both CTLs and NK cells...
  65. ncbi Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes
    I Zehbe
    Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Int J Cancer 94:711-6. 2001
    ..01). This observation may explain why L83V is a risk factor more in Sweden than in the other 2 countries...
  66. ncbi Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting
    Heather Griffin
    Division of Virology, National Institute for Medical Research, London NW7 1AA, UK
    J Mol Biol 355:360-78. 2006
    ....
  67. pmc Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection
    Rebecca M Richards
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:1522-7. 2006
    ..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition...
  68. pmc Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA
    Viviane Bechtold
    Swiss Institute for Experimental Cancer Research ISREC, 1066 Epalinges, Switzerland
    J Virol 77:2021-8. 2003
    ..Our results, together with those of others, suggest that any effect of the E2 protein on the expression of the E6 and E7 genes during the normal viral life cycle is of secondary importance compared to the function of E2 in replication...
  69. ncbi Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China
    T Li
    Laboratory of Genetics, Beijing Institute for Cancer Research, School of Oncology, Peking University, No. 1 Da Hong Luo Chang St, Beijing 100034, China
    Carcinogenesis 22:929-34. 2001
    ..These results suggest that HVP-16 plays a causative role in the high incidence of esophageal cancer in the Anyang region of CHINA:..
  70. ncbi Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression
    N Kivi
    Department of Virology, Haartman Institute, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Oncogene 27:2532-41. 2008
    ..These alterations may together lead to inhibition of apoptosis and facilitate the establishment of persistent infection in the epithelium...
  71. ncbi Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells
    Ni Sima
    Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, Hubei 430030, PR China
    Gynecol Oncol 106:299-304. 2007
    ....
  72. pmc Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
    A Hengstermann
    Institute of Biochemistry I, Medical Faculty, University of Cologne, Joseph-Stelzmann-Strasse 52, , Germany
    Proc Natl Acad Sci U S A 98:1218-23. 2001
    ....
  73. pmc Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein
    T Veldman
    Departments of Pathology and Oncology, Georgetown University Medical School, Washington, D.C. 20007, USA
    J Virol 75:4467-72. 2001
    ....
  74. ncbi Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region
    Kazunari Kondo
    Center for Pathogen Genomics, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    Virology 358:266-72. 2007
    ..The cross-neutralization appears to be correlated with conserved aa sequences among HPV types. The data in this study provide a basis for designing vaccine antigens effective against a broader spectrum of the high-risk HPVs...
  75. ncbi Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities
    Eva Kehmeier
    Department of Pharmacology and Toxicology, Philipps University Marburg, Karl von Frisch Strasse 1, D 35033, Germany
    Virology 299:72-87. 2002
    ..Analysis of functionally deficient HPV 16 E6 proteins in p53 null- and p53 wild-type-expressing cell lines revealed that the cellular steady-state level of this protein is influenced neither by its p53- nor its E6AP-binding abilities...
  76. ncbi Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts
    N Hafner
    Frauenklinik der Friedrich Schiller Universität, Jena, Germany
    Oncogene 27:1610-7. 2008
    ..Instead, constitutive expression of oncogene transcripts rather than the level of expression appears to be decisive for transformation and the maintenance of the malignant phenotype...
  77. ncbi Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanism
    R S Hegde
    Department of Biochemistry and Program in Structural Biology, New York University Medical Center, Skirball Institute of Biomolecular Medicine, 540 First Avenue, New York, NY, 10016, USA
    J Mol Biol 284:1479-89. 1998
    ....
  78. pmc Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2
    Ratish Gambhira
    Department of Pathology, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21231, USA
    J Virol 81:11585-92. 2007
    ..Further, vaccination with HPV16 L2 11-200 generates broadly cross-neutralizing serum antibody, suggesting the potential of L2 as a second-generation preventive HPV vaccine antigen...
  79. pmc CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model
    Tai Gyu Kim
    Department of Microbiology, The Catholic University of Korea, Seoul, Korea
    Immunology 112:117-25. 2004
    ..Thus, these data suggest that upon ODN stimulation DC might function as a potent adjuvant for E7 protein delivery for induction of protective cellular immunity against HPV E7-associated tumour challenge...
  80. ncbi Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer
    Chih Ming Ho
    Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, ROC
    Gynecol Oncol 102:54-60. 2006
    ..The aim of this prospective study was to analyze whether integration or high viral loads of human papillomavirus (HPV) is essential for malignant transformation of HPV types 52 and 58 as well as types 16 and 18...
  81. ncbi Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer
    I Nindl
    Department of Gynaecology, Gynaecologic Molecular Biology, Friedrich Schiller University, Jena, Germany
    Int J Cancer 82:203-7. 1999
    ..No statistically significant differences in the prevalence of the E6 or E7 prototype sequences, any variants or multivariants in German women with < or = CIN 1, CIN 2/3 or ICC were found...
  82. ncbi HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation
    Paola Massimi
    International Centre for Genetic Engineering and Biotechnology, Padriciano 99, Trieste I 34012, Italy
    Oncogene 23:8033-9. 2004
    ..These results suggest that in the context of HPV-induced transformation Dlg, MAGI-1 and MUPP1 can function as tumour suppressors...
  83. ncbi Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix
    Soraya Khouadri
    Laboratoire de Virologie Moléculaire du Centre de Recherche, Hôpital Notre Dame du Centre Hospitalier de l Université de Montréal, Montreal Quebec, Canada
    J Infect Dis 194:886-94. 2006
    ..We investigated the association between polymorphisms of human papillomavirus (HPV)-33 and squamous intraepithelial lesions (SILs)...
  84. ncbi p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development
    I Zehbe
    Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Cancer Res 61:608-11. 2001
    ..Moreover, the frequency of the arginine allele was similar in groups with different E6 genotypes. It is concluded that p53 arginine is a risk factor for cervical cancer but probably acts independently of E6 variants...
  85. ncbi Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA
    K Yamato
    Molecular Cellular Oncology and Microbiology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Cancer Gene Ther 13:234-41. 2006
    ....
  86. pmc Mechanisms of human papillomavirus-induced oncogenesis
    Karl Munger
    Department of Pathology, Harvard Medical School, 77 Ave Louis Pasteur, NRB 0958C, Boston, MA 02115 5727, USA
    J Virol 78:11451-60. 2004
  87. pmc Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16
    Arvind Varsani
    Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa and Department of Pathology, The Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    J Virol 77:8386-93. 2003
    ..Moreover, it contributes to knowledge of the structure of HPV-16 L1 VLPs and their derivatives...
  88. pmc Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines
    Christina Schellenbacher
    Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University Vienna, Austria
    J Virol 83:10085-95. 2009
    ....
  89. ncbi HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells
    F A Suprynowicz
    Department of Pathology, Georgetown University Medical School, Washington, DC 20057, USA
    Oncogene 27:1071-8. 2008
    ..Finally, the upregulation of caveolin-1 and ganglioside GM1 at the plasma membrane of E5-expressing cervical cells provides potential new therapeutic targets and diagnostic markers for high-risk HPV infections...
  90. ncbi Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice
    Tao Bian
    Biotech Center for Viral Disease Emergency, Yingxin Street 100, Xuanwu District, Beijing 100052, People s Republic of China
    Mol Cancer Ther 7:1329-35. 2008
    ..Chimeric capsomeres are capable of preventing and eliminating HPV16 infection. Therefore, our study has provided an economical vaccine candidate...
  91. pmc Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130
    K Smith-McCune
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco CA 94115, USA
    Proc Natl Acad Sci U S A 96:6999-7004. 1999
    ..Induction of E7 function was not correlated with binding to p130 or pRb but rather with intranuclear localization and modest induction of binding to p107...
  92. ncbi The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface
    Barbara Marchetti
    Institute of Comparative Medicine, Glasgow University Veterinary School, Garscube Estate, Glasgow G61 1QH, UK
    Oncogene 21:7808-16. 2002
    ..Lack of surface MHC I would have profound consequences for presentation of viral peptides to the immune system...
  93. ncbi The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors
    P Martin
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
    Cell 59:21-32. 1989
    ..We conclude that E5 may enhance the receptor activity via inhibition of receptor down-modulation...
  94. ncbi Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type
    S Nakagawa
    Department of Obstetrics and Gynecology, University of Tokyo, Faculty of Medicine, Bunkyo ku, Tokyo, Japan
    J Med Virol 62:251-8. 2000
    ..Thus, the present study demonstrates that E6 and E7 transcripts of HPV exist in virtually all HPV-positive cervical neoplasia specimens except for the absence of E7 transcripts in some of CINs...
  95. ncbi A promoter within the E6 ORF of human papillomavirus type 16 contributes to the expression of the E7 oncoprotein from a monocistronic mRNA
    Jacob A Glahder
    The DNA Tumour Virus Group, Institute of Molecular Pathology, The Protein Laboratory, University of Copenhagen, Panum Institute, Bldg 6 2, Blegdamsvej 3C, DK 2200 Copenhagen N, Denmark
    J Gen Virol 84:3429-41. 2003
    ..In conclusion, we have found that P542 is a relatively weak promoter compared with P97 and may be downregulated in differentiated epithelial cells...
  96. ncbi HPV episomal copy number closely correlates with cell size in keratinocyte monolayer cultures
    Peggy A Garner-Hamrick
    Genomics ID, Pharmacia Corporation, Kalamazoo, Michigan 49007, USA
    Virology 301:334-41. 2002
    ..The results also indicate that simple monolayer cultures may be useful for studying the relationship between differentiation, HPV DNA replication, and cell-cycle events...
  97. ncbi The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis
    Maria Filippova
    Department of Biochemistry and Microbiology, Center for Molecular Biology and Gene Therapy, Loma Linda University School of Medicine, Loma Linda, California 92354, USA
    J Biol Chem 279:25729-44. 2004
    ..These results support a model in which E6-mediated degradation of FADD prevents transmission of apoptotic signals via the Fas pathway...
  98. pmc Viral oncoproteins target the DNA methyltransferases
    W A Burgers
    Wellcome Trust CRUK Gurdon Institute, University of Cambridge, Cambridge, UK
    Oncogene 26:1650-5. 2007
    ..These observations open up the possibility that this association may be used to control cellular proliferation pathways and suggest a new mechanism by which small DNA tumour viruses can steer cells through the cell cycle...
  99. ncbi Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines
    D M Da Silva
    Cancer Immunology Program, Cardinal Bernardin Cancer Center, Department of Microbiology and Immunology, Loyola University Chicago, 2160 South First Avenue, Maywood, Illinois 60153, USA
    Virology 290:350-60. 2001
    ..This limitation could potentially be overcome by boosting with cVLPs containing the same target antigen incorporated into other papillomavirus-type VLPs...
  100. ncbi Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma
    Francoise Thierry
    Institute of Medical Biology, Singapore, Singapore
    Virology 384:375-9. 2009
    ..We will describe the role played by the viral E2 proteins in the transcriptional repression of the high risk HPV oncogenes and its implication in cervical cancer...
  101. pmc Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines
    Michael J Conway
    Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Virology 393:295-303. 2009
    ..These results suggest that Cys28 is necessary for late-stage stabilization of capsids, while Cys22 is necessary for proper display of L2 neutralizing epitopes...

Research Grants68

  1. Genomic instability induced by the HPV-16 E7 oncoprotein
    Stefan Duensing; Fiscal Year: 2009
    ....
  2. Dendritic Cell Immunotherapy for Cervical Cancer
    Alessandro Santin; Fiscal Year: 2004
    ..This study will determine whether E7 antigen-loaded autologous DC vaccination offers the potential of therapeutic benefit for patients with HPV16 or HPV18-associated cervical cancer. ..
  3. A Phase I/II Trial of a Therapeutic HPV Vaccine
    Cornelia Trimble; Fiscal Year: 2004
    ....
  4. THERAPEUTIC VACCINES FOR HPV DISEASES
    Cornelia Trimble; Fiscal Year: 2005
    ..These facilities will be used to develop Dr. Trimble's ability to design and execute clinical trials evaluating preneoplastic HPV-associated lesions of the female lower genital tract. ..
  5. Transcripitonal and Genetic Profiles in HNSCCs
    Elaine Smith; Fiscal Year: 2008
    ..abstract_text> ..
  6. CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16
    Mayumi Nakagawa; Fiscal Year: 2002
    ....
  7. Therapeutic DNA-MVA prime boost vaccination for HPV disease
    Cornelia Trimble; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  8. International Collaborative HNC Research
    Elaine Smith; Fiscal Year: 2007
    ..This aim is to determine whether there is an easily administered, sensitive biomarker that can predict HPV-HR status in HNC tumors prior to therapy.. [unreadable] [unreadable] [unreadable]..
  9. GENETIC EPIDEMIOLOGY AND MECHANISMS IN ORAL CANCER
    Elaine Smith; Fiscal Year: 2003
    ..abstract_text> ..
  10. Papillomavirus E2 as a cervical/anal cancer drug target
    Janet Brandsma; Fiscal Year: 2005
    ..Vectors containing a conditional wild-type CRPV E2 transgene will be used to determine the effects of E2 overexpression. ..
  11. MOLECULAR AND ONCOLOGIC VIROLOGY TRAINING PROGRAM
    Daniel DiMaio; Fiscal Year: 2005
    ..In these capacities, he is well positioned to foster interactions among other members of the faculty in the School of Medicine. ..
  12. Anthrax DNA vaccine for non-invasive immunization on skin
    Zhengrong Cui; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  13. A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli
    Zhengrong Cui; Fiscal Year: 2008
    ..The same vaccine or its modified version can also be used in agricultural industries to vaccinate cattle. [unreadable] [unreadable] [unreadable]..
  14. Activation of NF-kB by Human Papillomaviruses
    CRAIG WOODWORTH; Fiscal Year: 2006
    ..Therefore, our results will provide basic information on how HPV might alter host response to infection. [unreadable] [unreadable]..
  15. VSV-based Therapeutic Papilloma Vaccine
    Janet Brandsma; Fiscal Year: 2007
    ..The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer. ..
  16. Role of HPV16 E7/E2F6 interaction in viral oncogenesis
    Margaret McLaughlin Drubin; Fiscal Year: 2006
    ..These studies will further the understanding of how viral proteins interact with cellular factors to induce cancer. [unreadable] [unreadable] [unreadable] [unreadable]..
  17. ANALYSIS OF THE PDGF RECEPTOR JUXTAMEMBRANE DOMAIN
    Daniel DiMaio; Fiscal Year: 2004
    ..These experiments should provide new insights into the function and regulation of receptor tyrosine kinases and into human tumorigenesis, and they should elucidate the binding properties of a new family of WW domains. ..
  18. p53 loss in HMECs: a model of breast cancer prevention
    Victoria Seewaldt; Fiscal Year: 2007
    ..abstract_text> ..
  19. Real-Time Imaging of Hypoxia based on VHL Activity
    William Kaelin; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  20. Stress proteins in autoimmune depigmentation
    ISABELLE LE POOLE; Fiscal Year: 2005
    ..The same model will be of use to test the efficacy of therapeutic modalities to be developed for vitiligo in the future. ..
  21. Steroid As Cytoprotectants against Oxidative Toxicity
    Qin Chen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  22. ECM-Mediated Apoptosis in p53 (-) HMECs
    Victoria L Seewaldt; Fiscal Year: 2010
    ..Significance: Completions of these aims will provide insight into early events in ER(-) mammary carcinogenesis and provide novel targets for breast cancer chemoprevention. ..
  23. HIV AND EBV INTERACTION IN ORAL MUCOSAL EPITHELIUM
    Sharof Tugizov; Fiscal Year: 2005
    ..The results of these studies will provide new and detailed information on the mechanisms of HIV infection of the oral mucosal epithelium and the role of HIV-EBV infection in oral interepithelial LCs in HIV pathogenesis. ..
  24. Regulation of BRCA1 Function by Protein Phosphatase 1
    Lih Ching Hsu; Fiscal Year: 2009
    ..Lastly, we will also identify regulators of PP1 alpha activity toward BRCA1. ..
  25. Role of IGFBP -3 in mediating p53-induced apoptosis
    Adda Grimberg; Fiscal Year: 2006
    ..These studies also reflect Dr. Grimberg?s long-term career goals of exploring the interrelatedness of endocrine and oncologic molecular biology principles and applying them to clinical problems of dysregulated growth. ..
  26. High Throughput Screen for SMA
    Elliot Androphy; Fiscal Year: 2008
    ..The objective is to define structure activity relationships (SAR) for lead optimization and subsequently test available structural analogues to identify pharmacologically active drug-like compounds. [unreadable] [unreadable] [unreadable]..
  27. The Role of Phosphatase CL100/MKP1 in Human Cancer
    Gen Wu; Fiscal Year: 2009
    ..Collectively, our studies will provide important and novel insights into the role of CL100/MKP1 in cell cycle and apoptosis control in human cancer. ..
  28. COX-2 Inhibitors, APC and Colon Cancer Prevention
    Kotha Subbaramaiah; Fiscal Year: 2009
    ..These studies will enhance our understanding of the mechanistic link between COX-2 and colorectal cancer and potentially assist us in optimizing the use of selective COX-2 inhibitors as therapy. ..
  29. The XP Variant: A Human Mutator Gene for UV Damage
    James Cleaver; Fiscal Year: 2005
    ..We will express hRad3O on the keratin 14 promoter for over-expression in the skin, and make targeted knockout of mRad3O in vivo to identify roles for hRad3O in promoting and preventing carcinogenesis. ..
  30. A Luciferase Fusion Protein Library to Identify & Monitor Ubiquitylation Targets
    William Kaelin; Fiscal Year: 2008
    ..Reisolation of HIF in aims 2 and 3 would constitute proof of concept with respect to the potential utility of this approach. ..
  31. EBV BMRF-2 Protein in Infection of Oral Epithelial Cells
    Sharof Tugizov; Fiscal Year: 2007
    ..These data will greatly advance knowledge of the mechanisms of EBV infection of oropharyngeal epithelial cells and may be of value to design new approaches to prevention of initial EBV infection. ..
  32. MOLECULAR EPIDEMIOLOGY OF LUNG CANCER
    Chu Chen; Fiscal Year: 2010
    ..g. Rosaceae fruits and Cruciferae vegetables), and food-derived nutrients (e.g. carotenoids, vitamin C, and vitamin E). ..
  33. ORAL CANCER: MOLECULAR PROFILES & CLINICAL OUTCOMES
    Chu Chen; Fiscal Year: 2010
    ..HPV plays an important etiologic role in some oropharyngeal cancers, we plan to determine and incorporate HPV genotypes in the analyses and interpretation of the study findings. ..
  34. Clinical & Cost Effectiveness of HPV Vaccination in the US
    Sue Goldie; Fiscal Year: 2009
    ....
  35. EVOLUTION OF IMMUNE RECOGNITION AND EVASION
    Austin L Hughes; Fiscal Year: 2010
    ..In addition, by increasing our understanding of the population diversity and evolutionary history of human immune system genes, this research will enhance our knowledge of human immune function in health and disease. ..
  36. An RNA Sensor for Detection of Circulating Tumor Cells
    Gary Clawson; Fiscal Year: 2008
    ..abstract_text> ..
  37. Molecular markers of breast cancer risk and prevention
    Victoria L Seewaldt; Fiscal Year: 2010
    ....
  38. Integrin-Matrix Interaction in Cardiovascular Development
    Lester F Lau; Fiscal Year: 2010
    ..Together, these studies will provide novel insights into how CCN proteins regulate cardiovascular development through extracellular matrix signaling, and shed light on their roles in cardiovascular diseases. ..
  39. Study of genomic instability caused by HPV16 E6 and E7
    Dennis McCance; Fiscal Year: 2008
    ..abstract_text> ..
  40. Functional Role of ATM-Ab1-RNAP II Signaling Pathway
    Baskaran Rajasekaran; Fiscal Year: 2008
    ..abstract_text> ..
  41. FUNCTIONAL ANALYSIS OF THE E6AP UBIQUITIN PROTEIN LIGASE
    Peter Howley; Fiscal Year: 2007
    ..unreadable]..
  42. EFFECT OF HPV-16 E7 ON DIFFERENTIATING EPITHELIAL CELLS
    Dennis McCance; Fiscal Year: 2005
    ..Additionally, we will investigate the ability of E7 to increase cyclin/kinase activity in differentiating cells, which also contain high levels of kinase inhibitors. ..
  43. Gene Duplication and Genome Evolution
    Austin Hughes; Fiscal Year: 2004
    ..5) Examining the role of transposable elements in duplication of genomic segments by testing for nonrandom association between these elements and putatively duplicated blocks in the yeast genome. ..
  44. MOLECULAR MECHANISMS OF OXIDANT TOXICITY
    Qin Chen; Fiscal Year: 2004
    ..We have a unique finding of premature senescence with oxidative stress and will combine in vitro and in vivo approaches to uncover the trigger of unwanted effects of aging. ..
  45. SPONTANEOUS REGRESSION BIOMARKERS IN CERVIX DYSPLASIA
    Gloria Ho; Fiscal Year: 2003
    ..DNA typing of class II HLA alleles by PCR will be performed using blood collected at baseline. Associations between these factors and regression of CIN will be assessed by appropriate univariate and multivariate analyses. ..
  46. INDUCIBLE GENES IN ANGIOGENESIS AND TUMOR GROWTH
    LESTER LAU; Fiscal Year: 2003
    ..Third, the role of Cyr61 in tumor growth and metastasis will be evaluated, and intervention of Cyr61 activities will be explored as a means of restricting tumor growth. ..
  47. Mechanism of p12I and p30II in HTLV1 Infection
    Michael Lairmore; Fiscal Year: 2003
    ..Our long-term goal is to understand the role of p12-I and p30-II in the establishment of HTLV-1 infection in vivo. ..
  48. FUNCTIONS OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEIN
    Elliot Androphy; Fiscal Year: 2001
    ..Studies to test the ability of this E6BP peptide to inhibit E6 interactions with E6BP and p53 in vivo will be performed. ..
  49. CYR61-Mediated Angiogenesis in Rheumatoid Arthritis
    LESTER LAU; Fiscal Year: 2002
    ..Then we will explore Cyr61 as a potential therapeutic target. We will test whether blockade of Cyr6l function, using monoclonal antibodies or inhibitory peptides, can prevent or ameliorate arthritis and joint destruction. ..
  50. GENETIC EVENTS IN HUMAN PROSTATE CELL TRANSFORMATION
    David Jarrard; Fiscal Year: 2002
    ..In addition to addressing this critical mechanistic role in human prostate neoplasia, it will provide the applicant with a structured training program in molecular genetics in the laboratory of Dr. Catherine Reznikoff. ..
  51. Is Tissue ACE Required for Diabetic Renal Damage?
    Harold Franch; Fiscal Year: 2005
    ..We believe that this approach will not only critically test our hypothesis, but will also lay the ground work for future studies into the role of ACE in the diabetic kidney. ..
  52. Using Synthetic Lethality to Select Cancer Drug Targets
    William Kaelin; Fiscal Year: 2005
    ..Moreover, they may establish a new paradigm for the selection of anticancer drug targets based on inactivating mutations of TSG. ..
  53. Therapeutic Vaccine for EBV-associated Hodgkins Disease
    Rajiv Khanna; Fiscal Year: 2005
    ..The long-term aim of this project is to develop a rational basis for the delivery of a curative EBV-specific CTL immunity to not only in HIV patients with HD patients but also for non-HIV HD. ..
  54. Polymorphisms of INS/IGF Signal Pathways & Female Cancer
    Gloria Ho; Fiscal Year: 2006
    ..This genetic study, in conjunction with the ongoing serological study, will provide a comprehensive examination of the role of the insulin/IGF system in tumorigenes ..
  55. Aspirin, Inflammation Markers, and Colorectal Adenoma
    Gloria Ho; Fiscal Year: 2006
    ..It may also identify target populations (e.g., those with high levels of proinflammatory cytokines) who may benefit most from chemoprevention of aspirin. ..
  56. Genetic Analysis of Papillomavirus Virion Morphogenesis
    Craig Meyers; Fiscal Year: 2009
    ....
  57. Identification of downstream signals for Pitx2a
    Qize Wei; Fiscal Year: 2006
    ....
  58. HIV li-Key/Peptide Vaccine
    Minzhen Xu; Fiscal Year: 2002
    ..This entirely synthetic vaccine can be manufactured in a large scale and be given to those at high risk of HIV infection. ..
  59. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
    ..In initial studies, spores will be given subcutaneosly. Efficacy parameters will be defined as above. Successful trials can lead to phase I studies in humans, and treatment studies in non-human primates. ..
  60. li Suppression-enhanced HIV DNA Vaccine
    Minzhen Xu; Fiscal Year: 2003
    ..In a Phase II program Ii-RGC/gp120 DNA vaccines will be tested in non-human primates for the induction of a protective immune response against pathogenic HIV infection. ..
  61. CELL-SURFACE PROTEINS IN CAMPYLOBACTER FETUS VIRULENCE
    Martin Blaser; Fiscal Year: 2004
    ..Finally, the data generated can be used to develop a mathematical model of antigenic variation that focuses on the relationship between microbial recombination generating diversity and host selection determining the direction of change. ..
  62. H PYLORI RECOMBINATION AND GASTRIC COLONIZATION
    Martin Blaser; Fiscal Year: 2001
    ..pylori infections. ..
  63. High Throughput Screen for Compounds to Treat Papillomavirus Induced Cancers
    Elliot Androphy; Fiscal Year: 2007
    ..Success would impact the health of millions of women and men afflicted with HPV infections and associated malignancies. [unreadable] [unreadable] [unreadable]..
  64. PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT
    T C Wu; Fiscal Year: 2003
    ..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
  65. ENHANCEMENT OF HPV16 E6 & E7-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2001
    ..5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors. ..
  66. Selection of chemical inhibitors of oncoproteins
    Maurizio Bocchetta; Fiscal Year: 2002
    ..Furthermore, the experiments proposed may contribute novel technology for the over-expression and purification of potentially any protein in actively replicating human mesothelial cells. ..
  67. MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY
    Elliot Androphy; Fiscal Year: 2004
    ..Furthermore, SMN point mutants from SMA patients show defective oligomerization proportional to their disease severity. These studies have defined the genetic and biochemical basis for development of SMA. ..
  68. Papillomavirus Inhibitors for AIDS-related Malignancies
    Elliot Androphy; Fiscal Year: 2005
    ..The optimal cellular delivery system for the best inhibitors will be defined. The overall goal is to achieve high potency in cell-based models for eventual testing in animals and in human clinical trials. ..